Press Releases
Gildan Activewear Inc. (GIL) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - November 4, 2026) - Berger Montague, a leading national plaintiffs' law firm, announces a class action lawsuit against Gildan Activewear Inc. (NYSE: GIL) ("Gildan" or the "Company") on behalf of investors who purchased or acquired Gildan securities during the period from February 19, 2025 through June 15, 2026 (the "Class Period"). The deadline to apply for lead plaintiff is December 14, 2026...
Ceva Welcomes Introduction of Bluetooth High Data Throughput, Accelerating Next-Generation Wireless Connectivity
Early investment in Bluetooth HDT, integrated RF capabilities and proven interoperability drive strong commercial momentum, with more than ten customers already licensing Ceva's technology ROCKVILLE, Md., Nov. 4, 2026 /PRNewswire/ -- Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP for the Smart Edge, today welcomed the introduction of Bluetooth High Data Throughput (HDT), the next major advancement in Bluetooth technology...
Crocs™ Achieves Cradle to Cradle Certified® Circularity Gold for the Classic Clog, Marking a New Milestone in Circular Design and Recycled Material Innovation
This certification recognizes the brand designs three popular styles for circularity: the Classic Clog, Bae Clog and Keep It Going Classic Clog BROOMFIELD, Colo., Nov. 4, 2026 /PRNewswire/ -- Crocs, Inc. (NADSAQ: CROX), a world leader in innovative casual footwear for all, today announced the Crocs brand has achieved Cradle to Cradle Certified Circularity Gold Version 5.0 for its iconic Classic Clog...
Lemonade Expands Renters Insurance to Minnesota, Completing Nationwide Availability
Renters is the first Lemonade product available in all 50 states and Washington, D.C. NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lemonade (NYSE: LMND) today announced the availability of its renters insurance in Minnesota.
Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
Pelareorep-driven changes in the tumor microenvironment are associated with tumor responses and shrinkage Immune activation levels more than doubled in nearly all patients after one cycle of treatment Substantial increases in HPV-16-specific T cells and tumor-infiltrating lymphocytes observed when pelareorep is combined with a checkpoint inhibitor SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced new translational data from an ongoing study showing pelareorep's ability to increase human papillomavirus (“HPV”)-16-specific T cell clones and tumor-infiltrating lymphocyte (“TIL”) clones in second-line or later squamous cell anal cancer (“SCAC”) patients at the Society for Immunotherapy of Cancer (“SITC”) 2026 Annual Meeting. Pelareorep combined with a checkpoint inhibitor generated promising efficacy signals in second-line or later SCAC, including more than doubling the objective response rate and increasing median duration of response by 50% compared to the current approved therapy in that patient population...
NSJ Antimony Corp (NSJ) (9PZ0) Announces Completion of First Phase Drilling Program
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2026) - NSJ Antimony Corp. (CSE: NSJ) (FSE: 9PZ0) (the "Company" or "NSJ") announces completion of the first phase of drilling at its Antimony 2.0 project in New Brunswick, Canada. Highlights 11 drill holes completed, with 3,469 metres of NQ drilling...
Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
MGX-001 data establish preclinical proof-of-concept in hemophilia A On track to initiate global clinical trial in 2027
SKYX Announces That, Based on Growing Winter Demand, It Will Launch 4 New Plug & Play Turbo Heater Fan Models in 5 Different Colors
Upcoming Winter Launches of New Models in Sizes of 20'' 44” 52” and 60” are Expected in Home Depot, Lowes, Target, Walmart, Amazon and on Company's E-Commerce Platform Management Anticipates New Turbo Heater Models to Generate Significant Revenues During the Winter to Support Its Path to Cash-Flow Positive MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SKYX Platforms Corp. (NASDAQ: SKYX) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 120 patents and pending applications globally and 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today announced that based on growing sales and winter demand for its patented all-in-one turbo heater ceiling fan, it will launch an additional four models in larger and smaller sizes 20” 44” 52” and 60” and in five different colors including white, black, brush nickel, gold, and bronze in addition to its original 24” model. The combined ceiling fan and portable heater category is a multi-billion-dollar market, with tens of millions of units sold annually in the U.S. alone...
MEGL Secures US$100 Million Dedicated Credit Facility to Accelerate Cross-Border Timber Trading
HONG KONG, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Magic Empire Global Limited ("MEGL" or the "Company", Nasdaq: MEGL) today announced that it has secured a dedicated credit facility of US$100 million (the "Facility") from Anyu International Limited ("AIL") to fund its cross-border timber supply chain trading business. The Facility provides dedicated, medium-term capital support for the Company's timber procurement and cross-border trade settlement, and marks another concrete step in MEGL's strategic transformation into commodity trade and the timber industrial supply chain...
Clarivate Commences Offers to Purchase for Cash Certain of its Outstanding Debt Securities
LONDON, Nov. 4, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) ("Clarivate"), a leading global provider of transformative intelligence, today announced that its wholly-owned subsidiary, Clarivate Science Holdings Corporation (the "Company"), has commenced cash tender offers (collectively, the "Offers") to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 4, 2026 (the "Offer to Purchase"). The Company is offering to purchase in the Offers its 3.875% Senior Secured Notes due 2028 (the "2028 Notes") and its 4.875% Senior Notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes" and, each, a "Series of Notes") for the applicable consideration described below, subject to a $500,000,000 cap on the aggregate principal amount of Notes purchased in the Offers (the "Tender Cap"), proration and the terms and conditions, including, among others, a $400,000,000 cap on the aggregate principal amount of the 2028 Notes to be purchased and a $100,000,000 cap on the aggregate principal amount of the 2029 Notes to be purchased pursuant to the Offers (each, a "Series Cap") set forth in the Offer to Purchase...
RedCloud to Participate in the 15th Annual ROTH Technology Conference
LONDON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”), which is building the AI prediction infrastructure for global FMCG trade, today announced that Justin Floyd, Chief Executive Officer, will attend and host one-on-one meetings at the 15th Annual ROTH Technology Conference November 17-18, 2026 in New York City...
Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition
Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk MDS Three poster presentations will highlight data for TAVALISSE (fostamatinib disodium hexahydrate) in patients with chronic ITP and wAIHA SOUTH SAN FRANCISCO, Calif., Nov. 4, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b clinical study of R2891, a potent and selective inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with lower-risk myelodysplastic syndrome (MDS) who are relapsed or refractory (R/R) to prior therapies will be presented in an oral session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday, December 12, 2026...
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
Presentations highlight the role of the Delta Opioid Receptor (DOR) as a novel target central to the regulation of multiple genes involved in immune suppression, chemotaxis and proliferation of immune suppressing cells in cancer and autoimmune disease including MDSCs, T regs, and M2 macrophages TAMPA, Fla., Nov. 4, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it would present three posters on its research on the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of Myeloid-Derived Suppressor Cells (MDSCs) at the upcoming 68th American Society of Hematology (ASH) Annual Meeting and Exposition taking place on December 12-15, 2026, in New Orleans, Louisiana...
Immix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026
– Data will be presented on Monday, December 14, 2026 at 11:15 AM CDT – LOS ANGELES, CA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present an NXC-201 abstract at the upcoming American Society of Hematology (ASH) 68th Annual Meeting and Exposition to be held December 12-15, 2026, in New Orleans, LA. ASH Oral Presentation Details: Event 68th ASH Annual Meeting and Exposition, New Orleans, LA Title “45-patient safety and efficacy data for NXC-201 from Nexicart-2, the first U.S. trial of CAR-T in relapsed/refractory AL amyloidosis” Presentation Date/Time (Central Time) Publication #826 Session Date: Monday, December 14, 2026 Session Name: 652...
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
LONDON and GAITHERSBURG, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of abstracts submitted to the American Society of Hematology (ASH) Annual Meeting, to be held December 12-15, 2026, in New Orleans, Louisiana...
Terreno Realty Corporation Announces Lease in Avenel, NJ
BELLEVUE, Wash.--(BUSINESS WIRE)--Terreno Realty Corporation Announces Lease in Avenel, NJ.
Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that two of its T cell engager programs, CLN-049, a FLT3xCD3 T cell engager, and velinotamig (CLN-803), a BCMAxCD3 T cell engager, will be featured across four poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12-15 in New Orleans, Louisiana...
Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease
The three abstracts strengthen the clinical foundation for Iomab-ACT's development as a targeted conditioning platform for cellular and gene therapies across cancer and nonmalignant diseases Phase 1b/2 trial evaluates targeted immune conditioning with Iomab-ACT before standard commercial CD19-directed CAR T-cell therapy Memorial Sloan Kettering Cancer Center study demonstrates promise of Iomab-ACT as targeted conditioning agent before CAR T-cell therapy, with a focus on CAR T-cell expansion, immune cell depletion and treatment-related toxicities Clinical experience in severe sickle cell disease evaluates Iomab-ACT-based conditioning to support donor engraftment without conventional chemotherapy NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced the release of three abstracts for the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. The abstracts highlight clinical findings and continued development of Iomab-ACT, the Company's investigational CD45-targeted radioimmunotherapy, as a conditioning approach before CAR T-cell therapy and allogeneic stem cell transplantation for severe sickle cell disease...
Weekly Options Come to the 2X Long DRAM ETF (RAM)
Listed Options on the Roundhill T-REX 2X Long DRAM Daily Target ETF Will Add Weekly Expirations to the Existing Monthly Series Under the Cboe Weekly Program Tuttle Capital Management (TCM) announced that listed options on the Roundhill T-REX 2X Long DRAM Daily Target ETF (Cboe BZX: RAM) are being added to the Cboe Weekly Program effective October 15, 2026. RAM options currently trade with monthly expirations; weekly expirations will be added to them...
Harsco Rail Executes Agreement to Exit Deutsche Bahn Engineered-to-Order Contract and Receives Initial Payment from Sale of Project Assets to GBM
Deutsche Bahn (DB) agreement fully releases Harsco Rail from its obligations under the ETO contract, including elimination of its $13 million in performance bonds Harsco Rail received approximately $8 million in September from its former subcontractor General Atomics, Gleisbaumechanik Brandenburg GmbH (GBM), pursuant to an asset sales agreement related to the DB contract; Enviri expects to receive remaining payments of approximately $34 million in the coming quarters, including $15-18 mi llion in 2026 Enviri to record a net gain of approximately $19 million as a result of the GBM payment and with the execution of the DB agreement PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Enviri Corporation (NYSE: NVRI) today announced that it has entered into a definitive agreement with Deutsche Bahn (DB) that releases its Harsco Rail division from its engineered-to-order (ETO) contract for utility track vehicles. In conjunction with this agreement, Harsco Rail has repaid the advances previously received, totaling approximately $73 million, supporting the DB project...
Feedonomics Now Available in Amazon's Shop Direct Merchant Workspace, Making it Easier for Brands to Get Their Products in Front of Amazon Customers
AUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Commerce.com (Nasdaq: CMRC), the parent company of product intelligence platform Feedonomics, today announced that Feedonomics is available as a solution provider in Amazon's new Shop Direct Merchant Workspace, a free self-service portal that makes it easy for eligible merchants to register for Shop Direct, connect their stores to Amazon, and manage their participation in Amazon's agentic shopping program. Through the Merchant Workspace, eligible U.S. brands and retailers can select Feedonomics as their solution provider to connect their existing product catalogs to Shop Direct — using feeds they've already built for other shopping destinations...
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition
First clinical data for sutacimig in Factor VII deficiency (FVIID) shows multi-fold accumulation of endogenous FVII(a) with shortening of prothrombin time after a single subcutaneous dose in initial participants of the Phase 2b study
SoundHound AI and Ultraviolette Announce Major Expansion of Agentic Voice AI Across Global Electric Vehicle Lineup
SANTA CLARA, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- SoundHound AI, Inc. (NASDAQ: SOUN), a global leader in voice and agentic AI, and Ultraviolette Automotive , an innovator in future-ready electric mobility platforms and battery technology, today announced a major commercial expansion, with SoundHound set to power Ultraviolette's voice AI co-pilot...
Daré Bioscience to Present at Stifel's 2026 Healthcare Conference
SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Sabrina Martucci Johnson, Founder, President and Chief Executive Officer of Daré Bioscience, is scheduled to present at Stifel's 2026 Healthcare Conference happening November 10 – 12, 2026 in New York, New York...
Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML
Results report the safety of combining targeted alpha therapy with CLAG-M for patients with relapsed or refractory acute myeloid leukemia Long-term follow-up evaluates bone marrow recovery and potential delayed kidney and liver toxicities following Actimab-A plus intensive salvage chemotherapy Findings support development of Actimab-A as a potential mutation-agnostic AML backbone, building on prior clinical activity following venetoclax failure and in TP53-mutated disease NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced the release of an abstract for the 2026 American Society of Hematology (ASH) Annual Meeting and Exposition evaluating long-term safety and tolerability of Actimab-A (lintuzumab-Ac225) in combination with CLAG-M intensive salvage chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML). The abstract presents follow-up from a Phase 1 study of Actimab-A plus CLAG-M, with a focused analysis of blood count recovery and potential delayed kidney and liver toxicities among patients who survived at least three months after treatment...
Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that it will present data from multiple programs in its portfolio at the upcoming American Society of Hematology (ASH) Annual Meeting, which will be held in New Orleans, LA on December 12-15, 2026...
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placement of approximately $80 million of its common stock. The investors include ARCH Venture Partners, Adage Capital Management LP, Caligan Partners LP, RTW Investments, a leading mutual fund and other new and existing institutional investors...
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML –
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic CRISPR/Cas9 gene-edited chimeric antigen receptor (CAR) T cell therapy targeting CD19, will be presented in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12 to 15, 2026...
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
Agios announces new clinical data across company's rare hematology portfolio that will be featured in oral and poster presentations during ASH 2026.
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent with an “immune reset ”
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
– Week 48 Data from the Phase 3 SENTRY Trial Selected for Oral Presentation – – Data from the Phase 2 SENTRY-2 Trial Selected for Oral Presentation – NEWTON, Mass., Nov. 4, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the "Company"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that abstracts from two of its clinical trials evaluating selinexor in patients with myelofibrosis were selected for oral presentations at ASH 2026...
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Ronde-cel achieved a 91% overall response rate and 77% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 44 patients with 3L+ R/R LBCL in the PiNACLE pivotal trial Ronde-cel achieved a 95% overall response rate and 76% complete response rate; median progression-free survival not reached and estimated 6-month duration of complete response of 92% in 37 patients with 2L R/R LBCL in the Phase 1/2 trial No Grade ≥ 3 cytokine release syndrome was observed in either cohort and Grade ≥ 3 neurotoxicity was reported in < 10% of patients supporting outpatient administration SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that two abstracts featuring positive updated clinical data for rondecabtagene autoleucel (ronde-cel) have been accepted for presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans (ASH 2026)...
Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition
Data shows positive one-year safety and efficacy data from three patients enrolled in ongoing Phase 2 clinical trial being led by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) Safety profile consistent with results from soquelitinib T cell lymphoma and atopic dermatitis clinical trials SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that initial data from a Phase 2 clinical trial of soquelitinib for the treatment of patients with autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease, will be presented in a poster session at the 68th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place December 12-15, 2026 in New Orleans, LA...
Northrop Grumman to Participate in the Baird 2026 Global Industrial Conference
FALLS CHURCH, Va., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Northrop Grumman Corporation (NYSE: NOC) will participate in the Baird 2026 Global Industrial Conference on Wednesday, November 11.
Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that data from its CITY-FXI and CITY-TFR2 programs will be presented at the 68th American Society of Hematology (ASH) Annual Meeting, taking place December 12–15, 2026, in New Orleans, Louisiana...
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 14, 2026, from 7:00–8:30 a.m. CT / 8:00–9:30 a.m...
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
Media Release COPENHAGEN, Denmark; November 4, 2026 Twenty-two abstracts underscore the versatility of epcoritamab as monotherapy and in combination across multiple disease subtypes and in earlier lines of therapy Six oral presentations include first data disclosure from the Phase 3 EPCORE DLBCL-4 study evaluating epcoritamab in combination with lenalidomide in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) Genmab A/S (Nasdaq: GMAB) announced today that 22 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 68th Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 12-15, 2026, in New Orleans, Louisiana, and virtually. The breadth of data to be shared at ASH reflects continued progress across the comprehensive epcoritamab development program, including its evaluation in earlier lines of therapy and combination regimens across multiple B-cell malignancies...
Kelly® Earns Leader Recognition on Everest Group's U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix®
Kelly's technology business has been named a Leader on Everest Group's 2026 U.S. IT Contingent Talent and Strategic Solutions PEAK Matrix Assessment.
Truly Hard Seltzer Has Drinks Covered This Friendsgiving with a Custom Potluck Pack
The limited-edition Truly Potluck Pack is a custom mix of flavors built to pair with your specific menu, crew and vibe The limited-edition Truly Potluck Pack is a custom mix of flavors built to pair with your specific menu, crew and vibe
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program
ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy-evaluable r/r DLBCL patients Phase 2 marginal zone lymphoma IIT abstract shows robust and durable 93% ORR and 74.4% CRR with ZYNLONTA monotherapy Company to host conference call today at 4:15 p.m. EST LAUSANNE, Switzerland, Nov. 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced new and updated data from the ZYNLONTA (loncastuximab tesirine-lpyl) clinical program will be shared across multiple abstracts, including five oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting taking place December 12–15, 2026, in New Orleans, Louisiana...
Marriott International Celebrates 800th Property in Asia Pacific excluding China with the Opening of La Résidence Phou Vao, a Luxury Collection Resort & Spa, Luang Prabang
Marking the company's debut in Laos, the property invites travelers to experience the storied heritage of Luang Prabang from a 36-suite hilltop sanctuary, where Lao traditions live serenely alongside the French art de vivre. Download images here BETHESDA, Md.
Castor Maritime Announces that MPC Oceanic Group Has Entered into Agreement to Acquire a 41% Stake in Marlow Navigation
LIMASSOL, Cyprus, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Castor Maritime Inc. (NASDAQ: CTRM) (“Castor” or the “Company”), a diversified global shipping and energy company, announces that on November 4, 2026, its majority-owned subsidiary, MPC Oceanic Group AG (Deutsche Börse, Scale, ISIN DE000A1TNWJ4) (“MPC Oceanic Group”), entered into an agreement with the shareholders of Marlow Navigation Co. Ltd. (“Marlow”) to acquire a 41% stake in Marlow, a provider of crew and technical ship management services headquartered in Limassol, Cyprus...
FLOWERS FOODS ELECTS TWO NEW MEMBERS TO BOARD OF DIRECTORS
THOMASVILLE, Ga., Nov. 4, 2026 /PRNewswire/ -- Flowers Foods, Inc. (NYSE: FLO) today announced that its board of directors has elected Shaun P.
Panamint Capital Secures $1.8 Billion Green Loan for Largest Brownfield Renewable Energy Project in North America
INCLINE VILLAGE, Nev., Nov. 4, 2026 /PRNewswire/ -- Panamint Capital LLC, a leading energy infrastructure investor, has achieved financial close on the first phase of a $1.8 billion Green Loan to finance construction of Big Rooter Power, a 1.2 GWdc solar PV project located at the firm's Twin Oaks Power Station and Calvert Mine in Robertson County, Texas...
Netskope to Report Fiscal Third Quarter 2027 Financial Results on December 2, 2026
SANTA CLARA Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Netskope (NASDAQ: NTSK), a leader in modern security and networking for the cloud and AI era, today announced that it will release financial results for its fiscal third quarter ended October 31, 2026, after the market closes on Wednesday, December 2, 2026...
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License Application (BLA) Submission for Risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans...
CSX Executive Vice President and Chief Financial Officer to Address Baird Global Industrial Conference
JACKSONVILLE, Fla., Nov. 04, 2026 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) Executive Vice President and Chief Financial Officer, Kevin Boone, will address the 2026 Baird Global Industrial Conference in Chicago on Wednesday, November 11, at 10:05 a.m.
Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting
-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations, new data to highlight strong activity against additional non-Type 1 mutations -- -- Trial-in-progress presentation to highlight the ongoing CLARITY-101 Phase 1/1b trial of DMR-001 in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) -- WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the acceptance of preclinical data highlighting the best-in-class potential of DMR-001 for poster presentation at the 2026 ASH Annual Meeting and Exposition...
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells BRIDGEWATER, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that multiple abstracts were accepted for the 2026 American Society of Hematology (ASH) Annual Meeting, taking place December 12–15 in New Orleans, Louisiana...
Sumitomo Pharma America to Present New Clinical Data on Enzomenib and Nuvisertib at the 2026 American Society of Hematology Annual Meeting
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced two oral presentations and two poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 12-15, 2026, in New Orleans, Louisiana. The presentations will feature new clinical data on enzomenib, an investigational oral small molecule menin inhibitor being studied in genetic subtypes of relapsed or refractory (R/R) acute leukemia (AL), and nuvi...
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement
LAS VEGAS--(BUSINESS WIRE)--Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. Eligible public organizations subject to the French Public Procurement Code can now benefit from...
TrueFoundry Joins Okta's Cross App Access Ecosystem, Extending Workforce Identity Policies to AI Agents
SAN FRANCISCO--(BUSINESS WIRE)--TrueFoundry, the enterprise AI control plane, has announced support for the Cross App Access (XAA) protocol. AI agents connecting through the TrueFoundry AI Gateway can now operate under the same Okta policies organizations already apply to employees, reducing the custom security review that has slowed production deployments. Most AI agents running in production still authenticate with static API keys. These keys rarely expire, are seldom limited to a single task...
The FUTR Corporation Launches FUTR Agent Leads, Pairing Every Lead with a Business Agent and the FUTR Agent App
Businesses that buy leads get an agent that prepares their team and books the meeting, and customers get the FUTR Agent App to see the offer, share documents and pick a time Highlights FUTR Agent Leads grows the lead generation revenue FUTR started with FUTR Planning: businesses pay FUTR a fee for each qualified lead, and every lead comes with a business agent that works for the buyer and the FUTR Agent App, which works for the customer A business agent prepares your sales team, calls the lead ahead of time and runs practice calls, while the FUTR Agent App shows the customer your offer, helps them book a time and shares their documents through their secure FutureVault Customers earn FUTR Tokens for providing and validating their data and documents, and businesses can earn FUTR Tokens and use them toward leads[1] Toronto, Ontario--(Newsfile Corp. - November 4, 2026) - The FUTR Corporation (TSXV: FTRC) (OTCQB: FTRCF) (FSE: QA20) ("FUTR" or the "Company") today announced the launch of FUTR Agent Leads, a lead product that pairs every lead with a business agent working for the lead buyer and the FUTR Agent App working for the customer. FUTR Agent Leads builds on the lead generation business of FUTR Planning and is designed to help more leads turn into booked meetings and conversions...
From Payday to Showtime, OpenTable Reveals Americans Are Finding New Reasons to Dine Out in 2027
The brand's annual trend research shows how everyday celebrations, entertainment-fueled outings and the pursuit of worthwhile experiences are reshaping dining, led by younger generations SAN FRANCISCO, Nov. 4, 2026 /PRNewswire/ -- Americans aren't waiting for big milestones to make a dinner reservation. From celebrating everyday moments to turning a concert into a full night out, diners are finding more reasons to make moments feel special...
Leidos introduces HeadWay Dispatch for AI agent oversight
New platform helps organizations govern AI agents from different vendors and keep people in control of key decisions. RESTON, Va.
AvePoint Appoints Ali Rohani as Chief Strategy and Customer Officer
JERSEY CITY, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT; SGX: AVP), the AI Trust Company, today announced the appointment of Ali Rohani as Chief Strategy and Customer Officer, joining the AvePoint Executive Leadership Team.
BioMarin to Participate in Upcoming Investor Conferences
Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November...
SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy − − Patients with relapsed/refractory monocytic AML achieved a 54% ORR with a median overall survival (mOS) of 5.8 months and patients with TP53-mutated AML achieved a 57% ORR and a mOS of 8.8 months, comparing favorably to historical outcomes in these adverse-risk settings of ~2.5 months − − Study showed that SLS009 (tambiciclib) combination was well-tolerated with no meaningful added toxicity − NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from its completed Phase 2 study of SLS009 (tambiciclib) for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12–15, 2026 in New Orleans. This Phase 2 trial evaluated SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine (AZA) and venetoclax (VEN) for the treatment of patients with r/r AML after prior VEN-based treatment...
Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026
– 14 accepted revumenib abstracts, including 7 for oral presentation, reinforce Syndax's scientific leadership in menin inhibition – – Revumenib abstracts highlight encouraging activity across multiple acute leukemia subtypes and settings, including frontline, post-transplant maintenance, and MRD relapse – – Real-world data showcase compelling results in R/R NPM1m or KMT2Ar acute leukemia patients who received revumenib monotherapy or combination therapy – – 5 accepted axatilimab abstracts, including long-term data that highlight the potential for prolonged clinical benefit with axatilimab in R/R cGVHD – – Company to host investor event and webcast on Monday, December 14, 2026, at 7:00 a.m. CT/8:00 a.m...
Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition
Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site activation advances, first patient dosing remains on track for 1Q 2027 and FDA filing for accelerated approval remains targeted for 1H27 FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters highlighting compelling data and clinical progress for its lead radiopharmaceutical candidate, iopofosine I 131 in Waldenström macroglobulinemia (WM), will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 12 – 15 in New Orleans, Louisiana...
Vivakor Highlights Direct Midstream's New Mexico Operating Agreement as Proposed Acquisition Advances
Conditional agreement covering 52 wells could generate more than $2 million in annual service revenue for Direct Midstream at targeted operating levels Dallas, TX, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vivakor, Inc. (Nasdaq: VIVK) ("Vivakor" or the "Company"), an integrated provider of energy transportation, storage, reuse and remediation services, today highlighted a new commercial opportunity at Direct Midstream, LLC (“Direct Midstream”), the subject of Vivakor's previously announced proposed $40 million acquisition. As announced today on Direct Midstream's website, Direct Midstream has entered into a conditional agreement with Phoenix Energy Solutions, LLC (“PES”) to operate a portfolio of 52 oil production and saltwater disposal wells in New Mexico...
EQUINOX ANNOUNCES HOUSE OF EQUINOX, AN IMMERSIVE EXPLORATION OF ALIVENESS
The exclusive four-day New York City experience, presented by American Express, brings Equinox's philosophy of Aliveness to life through movement, recovery, and sensory experiences NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Equinox , the authority in high-performance luxury lifestyle, announces House of Equinox, an immersive wellness experience presented by American Express at Thirty-Five Off Madison in New York City from November 12–15, 2026. The experience, exclusively available to eligible American Express Card Members through the Premium Events Collection™, is designed to explore what it truly means to feel alive, discovering the connection between physical energy, emotional vitality, and human connection...
OpenTable Reveals the Top 100 Restaurants in America for 2026
California leads with 19 honorees, while New York City and Chicago stand out among cities SAN FRANCISCO, Nov. 4, 2026 /PRNewswire/ -- The next great meal could be across the country, or just around the corner. Today, OpenTable, a global leader in restaurant tech, unveils its Top 100 Restaurants in America for 2026 1, celebrating the restaurants diners sought out and loved this year...
Mediaocean Expands Prisma Direct to Search with Microsoft Advertising Integration
NEW YORK--(BUSINESS WIRE)--Mediaocean Expands Prisma Direct to Search with Microsoft Advertising Integration.
Adobe Integrates Agentic CX Enterprise Coworker Into AI Platforms from Anthropic, Google, Microsoft, OpenAI and More
SAN JOSE, Calif.--(BUSINESS WIRE)--Adobe (Nasdaq:ADBE), the global technology leader that unleashes creativity, productivity and customer experiences through innovative tools and platforms, today announced that Adobe CX Enterprise Coworker, the industry's leading agentic teammate for customer experience orchestration, is now available within leading AI platforms including ChatGPT (as a plugin), Claude, Databricks Genie, Gemini for business and Microsoft Copilot – with availability in Amazon Qui...
Credo and Oracle Advance Optical Transceiver Telemetry Standardization with OCP Community
SAN JOSE, Calif.--(BUSINESS WIRE)-- #WeConnect--Credo and Oracle advance optical transceiver telemetry standardization with OCP Community.
CoStar Raises Near-Term U.S. Retail Forecast
ARLINGTON, Va.--(BUSINESS WIRE)--U.S. retail projections are expected to improve in the near-term, according to a revised forecast from CoStar, a leading global provider of online real estate marketplaces, information and analytics in the property markets. National retail vacancy is now forecasted to end the year at 4.26%, down from 4.32% in the third quarter. Asking rent growth is estimated to reach $26.36 per square foot at the end of the year before rising to $27.12 per square foot by the en...
Invesco Ltd. to Participate in the BMO Financials Conference
ATLANTA, Nov. 4, 2026 /PRNewswire/ -- Invesco Ltd. (NYSE: IVZ), a leading global asset management firm, announced today that Chief Financial Officer Allison Dukes will participate in a fireside chat at the BMO Financials Conference on November 9, 2026 at 1:15 p.m.
Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting
BERKELEY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today announced that vispa-cel and CB-011 clinical abstracts have been accepted for two oral presentations and one poster presentation at the 2026 American Society of Hematology (ASH) Annual Meeting, which will be held December 12-15, 2026 in New Orleans, Louisiana...
Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition
WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for budoprutug in immune thrombocytopenia (ITP) at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, Louisiana from December 12-15, 2026...
Royale Energy to Commence Trading on OTCQB® Venture Market
SAN DIEGO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Royale Energy, Inc. (OTCQB: ROYL) (“Royale” or the “Company”) today announced that its common stock is scheduled to commence trading on the OTCQB Venture Market, operated by OTC Markets Group Inc., effective Wednesday, November 4, 2026, under the ticker symbol ROYL. The commencement of trading on OTCQB represents an important milestone in Royale's ongoing efforts to strengthen its capital markets position, enhance transparency and improve access to the investment community...
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for acute myeloid leukemia Data will be presented in a poster session at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026 COPENHAGEN, Denmark, November 4, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), in a poster session at the American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana, December 12-15, 2026. The data further validate the potential of EVX-04 as an off-the-shelf therapeutic vaccine for AML, demonstrating broad patient coverage, conserved target expression across disease stages and the induction of ERV-specific T-cell responses in humanized mice...
Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026
FOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that six abstracts have been accepted for poster presentation at the 68th American Society of Hematology (ASH) Annual Meeting, to be held December 12-16, 2026, in New Orleans, LA...
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek 2026 Featuring Leading PBH Experts.
Codere Online to Release Financial Results for the Third Quarter 2026 on November 12th
Madrid, Spain and Tel Aviv, Israel, November 4, 2026 (GLOBE NEWSWIRE) – Codere Online Luxembourg, S.A. (Nasdaq: CDRO / CDROW) (the “Company” or “Codere Online”) a leading online gaming operator in Spain and Latin America, today announced that it will release its third quarter 2026 results prior to 8:30AM US Eastern Time on November 12, 2026...
NBA and ServiceNow extend partnership to enhance employee experience with ServiceNow EmployeeWorks
SANTA CLARA, Calif.--(BUSINESS WIRE)---- $NOW #NBA--ServiceNow (NYSE: NOW) today announced its extended partnership with the National Basketball Association (NBA) as its Official Employee Workflow Partner. The NBA will deploy ServiceNow EmployeeWorks to create a self-service experience for NBA employees to manage onboarding and internal workplace service requests, allowing them to complete tasks in one experience through one platform.The expanded partnership builds on the NBA's existing use of ServiceNow tech...
Guided Therapeutics Provides Update on its Cervical Cancer Screening Study with Türkiye's Ministry of Health
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced that its landmark cervical cancer screening study, conducted with Türkiye's Ministry of Health (TMOH), has enrolled over 250 of the expected 800 women needed to complete the study. The study, funded by TMOH, is intended to support Türkiye's plan to use LuViva to screen up to 20 million Türkish women annually. Said Mark Faupel, GTHP's CEO, “While we are stil...
Abnormal AI Names Don Jeter CMO to Accelerate Its Expansion in AI Security
LAS VEGAS--(BUSINESS WIRE)--Abnormal AI Appoints Don Jeter as CMO.
IonQ Announces Partnership with QuantumCT to Expand Quantum Computing Access
COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world's leading full-stack quantum platform and foundry, today announced a partnership with QuantumCT, Connecticut's statewide initiative to accelerate quantum innovation and economic development. QuantumCT will purchase access to IonQ's trapped-ion quantum computers on behalf of Connecticut-based, quantum-focused organizations. Under the agreement, QuantumCT will make IonQ's cloud quantum computing resources available to its network of...
Tom Thumb, Albertsons and Randalls Launch Holiday Bucks Campaign to Raise $1 Million for Local Nonprofits Fighting Hunger
ARLINGTON, Texas--(BUSINESS WIRE)--Tom Thumb, Albertsons and Randalls today announced Holiday Bucks, a four-week campaign to raise $1 million for local nonprofits fighting hunger.
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
NEW YORK, Nov. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, being held November 11, 2026 in New York City. Lishan Aklog, M.D...
BWX Technologies, Inc. Launches Cash Tender Offers and Consent Solicitations for its 4.125% Senior Notes due 2028 and 4.125% Senior Notes due 2029
LYNCHBURG, Va.--(BUSINESS WIRE)--BWX Technologies, Inc. (NYSE: BWXT) (“BWXT”) announced today that it has commenced (i) offers to purchase for cash (the “Offers”) from each holder and beneficial owner (each, a “Holder”) any and all of its outstanding 4.125% Senior Notes due 2028 (CUSIP Nos. 05605H AB6 / U12213 AB7) (the “2028 Notes”) and 4.125% Senior Notes due 2029 (CUSIP Nos. 05605H AC4 / U12213 AC5) (the “2029 Notes” and, together with the 2028 Notes, the “Notes” and each, a “Series”) and (i...
BWX Technologies, Inc. Announces Proposed Offering of Senior Notes
LYNCHBURG, Va.--(BUSINESS WIRE)--BWX Technologies, Inc. (NYSE: BWXT) announced today that it has launched an offering of $500 million aggregate principal amount of senior unsecured notes due 2034 (the “Notes”) in a private transaction exempt from the registration requirements of the Securities Act of 1933, as amended (the “Act”). The Notes will be guaranteed by each of BWXT's present and future wholly-owned subsidiaries that are obligors under its existing credit agreement. BWXT intends to use...
TOMI Environmental Solutions, Inc. Announces Recurring Consumable Agreement with Global Eye Health Company
FREDERICK, Md., Nov. 04, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced an expanded relationship with a leading global eye health company that develops and commercializes contact lenses, lens-care products, ophthalmic pharmaceuticals, and surgical technologies for eye-care professionals and patients worldwide...
Parabolic Technologies, Inc. Announces Pricing of $13.5 Million Underwritten Public Offering
Parabolic Technologies (PARA) priced a $13.5M underwritten public offering with warrants; net proceeds fund general corporate purposes and working capital.
OneMedNet Receives Mid Six-Figure Re-Order from Foundation Model Company Developing Radiology Models
MINNEAPOLIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced that it has received a mid six-figure re-order from a previously announced foundation model company developing advanced AI models for radiology. This order follows OneMedNet's delivery of the first dataset under the customer agreement — based on the quality and completeness of that data...
BrenX Reports Preliminary Results Indicating Approximately 40% Lower Steam Energy Costs at Tempo Beverages
Estimated Customer Savings of Approximately US$1.0 Million per Year and US$15 Million Over 15 Years Assuming Current Performance Is Sustained Rosh HaAyin, Israel--(Newsfile Corp. - November 4, 2026) - BrenX Ltd. (NASDAQ: BRNX), a provider of thermal energy storage and integrated industrial energy solutions, today reported preliminary results from its 32 MWh bGen™ thermal energy storage system at Tempo Beverages ("Tempo") in Israel...
IonQ Completes Acquisition of Elisity, Extending Quantum Security for Enterprises and Government
COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world's leading full-stack quantum platform and foundry, today completed its acquisition of Elisity, Inc., a Zero Trust security company, in an all-stock transaction. The combination extends IonQ's quantum security strategy, adding Zero Trust technology that complements IonQ's post-quantum cryptography (PQC) and quantum key distribution (QKD) capabilities. These combined enhancements are intended to protect customers today, and keep the...
Luxfer Shareholders Approve Acquisition by Wynnchurch Capital
RIVERSIDE, Calif.--(BUSINESS WIRE)--Luxfer Holdings PLC (NYSE: LXFR) (“Luxfer” or the “Company”), a global industrial company innovating niche applications in materials engineering, today announced that its shareholders voted to approve the Company's previously announced acquisition by affiliates of Wynnchurch Capital, L.P. (“Wynnchurch”) at two meetings of shareholders held earlier today in London, United Kingdom. Under the terms of the transaction, Company shareholders will receive $17.37 per...
Siebert Financial Announces Next Generation Leadership Structure to Drive Continued Growth as Firm Enters 60th Year
MIAMI BEACH, Fla. & NEW YORK--(BUSINESS WIRE)--Siebert Financial Corp. (NASDAQ: SIEB) (“Siebert”), a diversified provider of financial services, today announced a new leadership structure designed to support the company's continued growth as it enters its 60th year in 2027 and reinforce the long-term leadership of the Gebbia family across generations.John J. Gebbia has been named Chairman of the Board of Siebert Financial, continuing his leadership of the company and providing strategic guidance...
Voya Financial Expands its Multiple Employer Solutions as Business Nearly Doubles
WINDSOR, Conn.--(BUSINESS WIRE)--Voya Financial, Inc. (NYSE: VOYA) today announced new capabilities that will expand its Multiple Employer Solutions (MES) business, giving employers, workers and advisors more choice and a simpler experience. Voya's MES business serves a wide range of organizations, including industry associations, faith-based groups, public sector entities, professional employer organizations and small-to-middle market businesses. Over the past two years, Voya's MES business ha...
SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026
DENVER, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Wednesday, November 11, 2026, and host a webcast and conference call to discuss its financial results and business progress...
CRH announces Cash Tender Offers, Exchange Offers and Consent Solicitations for Arcosa, Inc. Notes
NEW YORK--(BUSINESS WIRE)--In connection with the recent completion of the acquisition of Arcosa, Inc. (“Arcosa”) on October 23, 2026 (the “Arcosa Acquisition”), CRH plc (NYSE: CRH) announced today that CRH America Finance, Inc. (“CRH AF”), an indirect wholly owned subsidiary of CRH plc, has commenced (i) cash tender offers (the “Tender Offers” and each a “Tender Offer”) to purchase any and all of the outstanding 4.375% Senior Notes due 2029 (the “2029 Arcosa Notes”) and 6.875% Senior Notes due...
Stevanato Group (STVN) Shareholder Investigation Following Stock Decline – Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of Stevanato Group (STVN) investors following the Company's stock price decline
Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026
Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in London SAN JOSE, Calif., Nov. 4, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Robert Wenham, M.D...
GMG Signs Binding Distribution Agreement with Brenntag for Exclusive European Distribution of Graphene Products
Brisbane, Queensland, Australia--(Newsfile Corp. - November 4, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has signed an exclusive Distribution Agreement ("Agreement") with Brenntag Química, S.A.U. (XETR: BNR) of Spain ("Brenntag") to set out the terms of the sale and distribution of GMG's Graphene Products, initially THERMAL-XR, G-LUBRICANT and G-FLUID products within Europe, initially for Spain, Italy and Portugal...
SpaceX Selects Qualcomm to Accelerate Starlink Mobile's Nationwide 5G Network
SAN DIEGO--(BUSINESS WIRE)--Qualcomm Technologies, Inc. today announced that SpaceX has selected Qualcomm Dragonwing™ Cellular Infrastructure platforms for its Starlink Mobile U.S. nationwide terrestrial 5G network. Powered by the Qualcomm Dragonwing™ QRU100 and QDU100 platforms and commercial-grade Layer 1 software, the network will combine high-capacity Massive MIMO radio and baseband technology and power-efficient processing to support cellular base station deployment at scale. The collabora...
Idaho Copper to Host Virtual Investor Webinar on Wednesday, November 16, 2026
Management to Discuss Updated Preliminary Economic Assessment for the CuMo Project, Including After-Tax NPV of US$1.88 Billion, 18.5% IRR and 46-Year Mine Life